Testing an immune-boosting injection for early memory loss

Plain-English translation of NCT05606341 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

Researchers are testing an experimental medication called CpG 1018 to see if it can help people with early memory problems caused by Alzheimer's disease. The medication works by waking up the immune system to fight disease in the brain. This early-stage trial focuses on safety—making sure the treatment is well-tolerated and doesn't cause harmful side effects.

Current Alzheimer's treatments have limited effectiveness, and researchers are exploring new ways to harness the body's own immune system to slow or stop the disease. This medication is designed to stimulate the immune system differently than existing drugs, offering a potentially new approach for people in the early stages of cognitive decline.

Do you qualify?

You likely qualify if…

you are between 65 and 85 years old
you have been diagnosed with mild memory loss due to Alzheimer's disease or mild Alzheimer's dementia
you have a positive brain scan showing amyloid protein buildup (a hallmark of Alzheimer's)
you score 17 or higher on a cognitive assessment test
you have a trusted family member or friend who can help track your health and attend appointments with you

You likely don't qualify if…

you have a history of serious mental health conditions like hallucinations, severe depression, or suicidal thoughts
you have an autoimmune disorder or a history of severe asthma or serious infections
you are currently taking corticosteroids, immunosuppressive drugs, or blood thinners
you have had a stroke, mini-stroke, or seizures in the past 12 months
you have been exposed to COVID-19 or have COVID-like symptoms within the past 2 weeks

What participation looks like

You will receive three injections over 8 weeks—one at the start, one at week 4, and one at week 8. Each injection is given in the morning and takes about an hour total (including a one-hour observation period afterward to monitor for any reactions). Roughly two-thirds of participants will receive the medication at different dose levels, and one-third will receive a placebo (salt water) as a comparison. You'll be monitored carefully to see how safe and tolerable this treatment is.

AI-generated summary from trial data · Jun 16, 2026 · Not medical advice

Trial locations(1 site)

United States

NYU Langone Health, New York, New York